Public health emergency declared in the Carolinas ahead of Hurricane Florence

The Department of Health and Human Services has declared a public health emergency in North Carolina and South Carolina ahead of the incoming Category 4 Hurricane Florence, which is expected to make landfall later this week.

The storm is expected to dump between 20 inches and 40 inches of rain, producing catastrophic flooding and a life-threatening storm surge up to 13 feet, according to reports. Strong winds of 140 mph have been recorded in the storm, which is currently crawling across the Atlantic Ocean as of Wednesday morning.

HHS Secretary Alex Azar declared the state of emergency for both states on Sept. 11. Residents of the Carolinas can expect the storm to hit between Friday and Saturday, though rain could linger for days. Communities along the Carolina coast have been issued mandatory evacuations.

At least some hospitals expected to be impacted are evacuating and moving patients. Other South Carolina hospitals have closed new admissions, but will keep emergency departments open to the public until three hours before winds affect the area, with full closures scheduled for Wednesday evening, according to local reports.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.